Bacteraemic pneumococcal pneumonia: current therapeutic options (Q37833059)

24 August 2017

1 reference

title

Bacteraemic pneumococcal pneumonia: current therapeutic options (English)

1 reference

24 August 2017

0 references

pneumococcal pneumonia

1 reference

Ronald Anderson

2

1 reference

ORCID Public Data File 2021

author name string

Charles Feldman

series ordinal

1

1 reference

24 August 2017

1 January 2011

1 reference

24 August 2017

1 reference

24 August 2017

71

1 reference

24 August 2017

2

1 reference

24 August 2017

131-153

1 reference

https://scigraph.springernature.com/pub.10.2165/11585310-000000000-00000

24 August 2017

0 references

cites work

New insights into pneumococcal disease.

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Pathogenesis, treatment, and prevention of pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

A comparative study of bacteremic and non-bacteremic pneumococcal pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Bacteraemic pneumococcal pneumonia in COPD patients: better outcomes than expected

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Early predictors of mortality in pneumococcal bacteraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Economic aspects of pneumococcal pneumonia: a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Streptococcus pneumoniae colonisation: the key to pneumococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Inhibitory and bactericidal effects of hydrogen peroxide production by Streptococcus pneumoniae on other inhabitants of the upper respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Commensal pathogens, with a focus on Streptococcus pneumoniae, and interactions with the human host

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

The effects of pneumolysin and hydrogen peroxide, alone and in combination, on human ciliated epithelium in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Pneumolysin: a double-edged sword during the host-pathogen interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Hyaluronidase augments pneumolysin-mediated injury to human ciliated epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Virulence factors in pneumococcal respiratory pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Streptococcus pneumoniae: virulence factors and variation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Plasminogen- and fibronectin-binding protein B is involved in the adherence of Streptococcus pneumoniae to human epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Sialic acid: a preventable signal for pneumococcal biofilm formation, colonization, and invasion of the host.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Resistance to mucosal lysozyme compensates for the fitness deficit of peptidoglycan modifications by Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Species-specific interaction of Streptococcus pneumoniae with human complement factor H.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Evolving concepts in biofilm infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Hospitalization for respiratory syncytial virus infection and invasive pneumococcal disease in Danish children aged <2 years: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Association of respiratory virus activity and environmental factors with the incidence of invasive pneumococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Pneumolysin activates the synthesis and release of interleukin-8 by human neutrophils in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Epithelial cells are sensitive detectors of bacterial pore-forming toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Phosphatase-dependent regulation of epithelial mitogen-activated protein kinase responses to toxin-induced membrane pores

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

MKP1 regulates the induction of MCP1 by Streptococcus pneumoniae pneumolysin in human epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Proinflammatory interactions of pneumolysin with human neutrophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Pneumolysin potentiates production of prostaglandin E(2) and leukotriene B(4) by human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

The role of pneumolysin in mediating lung damage in a lethal pneumococcal pneumonia murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Role of Toll-like receptors 2 and 4 in pulmonary inflammation and injury induced by pneumolysin in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Interleukin-17A mediates acquired immunity to pneumococcal colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Low CD4 T cell immunity to pneumolysin is associated with nasopharyngeal carriage of pneumococci in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Novel approaches to the identification of Streptococcus pneumoniae as the cause of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Streptococcus pneumoniae DNA load in blood as a marker of infection in patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Diagnosis of Streptococcus pneumoniae infections in adults with bacteremia and community-acquired pneumonia: clinical comparison of pneumococcal PCR and urinary antigen detection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Usefulness of real-time PCR for lytA, ply, and Spn9802 on plasma samples for the diagnosis of pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Assessment of inflammatory markers in patients with community-acquired pneumonia--influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Diagnostic utility of the soluble triggering receptor expressed on myeloid cells-1 in bronchoalveolar lavage fluid from patients with bilateral lung infiltrates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Antimicrobial-resistant Streptococcus pneumoniae: trends and management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Update on community-acquired pneumonia: impact of antibiotic resistance on clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Clinical outcomes of bacteremic pneumococcal infections in an area with high resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Stretching the mutant prevention concentration (MPC) beyond its limits

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

What have we learned from pharmacokinetic and pharmacodynamic theories?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Antimicrobial susceptibility of pneumococcal isolates causing bacteraemic pneumococcal pneumonia: analysis using current breakpoints and fluoroquinolone pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Administration of first hospital antibiotics for community-acquired pneumonia: does timeliness affect outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Treatment and outcomes for patients with bacteremic pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Recent advances in community-acquired pneumonia: inpatient and outpatient

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Therapy for pneumococcal bacteremia: monotherapy or combination therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Macrolides and community-acquired pneumonia: is quorum sensing the key?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Adjunctive therapy in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

The effects of ketolides on bioactive phospholipid-induced injury to human respiratory epithelium in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Pneumococcal meningitis in adults: new approaches to management and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Effects of systemic steroids in patients with severe community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Hydrocortisone therapy for patients with septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

New molecular targets for the treatment of neutrophilic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Cyclic AMP: master regulator of innate immune cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Effect of rolipram and dibutyryl cyclic AMP on resequestration of cytosolic calcium in FMLP-activated human neutrophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Beta-adrenergic receptor-dependent and -independent stimulation of adenylate cyclase is impaired during severe sepsis in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Effects of pentoxifylline on coagulation profile and disseminated intravascular coagulation incidence in Egyptian septic neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Pentoxifylline in preterm neonates: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Adjunctive immunologic interventions in neonatal sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Bacteraemic pneumococcal pneumonia: Impact of HIV on clinical presentation and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal Bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Predicting bacteremic pneumonia in HIV-1–infected patients consulting the ED

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Hospitalizations for Invasive Pneumococcal Disease Among HIV-1–Infected Adolescents and Adults in the United States in the Era of Highly Active Antiretroviral Therapy and the Conjugate Pneumococcal Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Failure of Macrolide Antibiotic Treatment in Patients with Bacteremia Due to Erythromycin‐Resistant Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585310-000000000-00000

Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription

21 January 2018

1 reference

12 December 2020

Guidelines and quality for community-acquired pneumonia: measures from the Joint Commission and the Centers for Medicare and Medicaid Services

1 reference

12 December 2020

Corticosteroids for acute bacterial meningitis

1 reference

12 December 2020

Quality of medical care delivered to Medicare beneficiaries: A profile at state and national levels

1 reference

12 December 2020

Mechanisms of myocardial depression in sepsis

1 reference

12 December 2020

In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure

1 reference

12 December 2020

Pneumococcal surface adhesin A (PsaA): a review

1 reference

12 December 2020

Impaired beta-adrenergic receptor stimulation of cyclic adenosine monophosphate in human septic shock: association with myocardial hyporesponsiveness to catecholamines

1 reference

12 December 2020

Impaired antibody response to pneumococcal capsular polysaccharides and phosphorylcholine in adult patients with a history of bacteremic pneumococcal infection

1 reference

12 December 2020

Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro

1 reference

12 December 2020

Antibiotic timing and diagnostic uncertainty in Medicare patients with pneumonia: is it reasonable to expect all patients to receive antibiotics within 4 hours?

1 reference

12 December 2020

Does penicillin remain the drug of choice for pneumococcal pneumonia in view of emerging in vitro resistance?

1 reference

12 December 2020

The impact of time on the systemic inflammatory response in pneumococcal pneumonia

1 reference

12 December 2020

Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells

1 reference

12 December 2020

Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection

1 reference

12 December 2020

Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis

1 reference

12 December 2020

Determinants of outcome in patients with bacteraemic pneumococcal pneumonia: Importance of early adequate treatment

1 reference

12 December 2020

Phosphorylcholine determinants in six pneumococcal capsular polysaccharides detected by monoclonal antibody

1 reference

12 December 2020

Pharmacological control of neutrophil-mediated inflammation: strategies targeting calcium handling by activated polymorphonuclear leukocytes

1 reference

12 December 2020

Hypochlorite scavenging by Pseudomonas aeruginosa alginate

1 reference

12 December 2020

Circulating levels of soluble triggering receptor expressed on myeloid cells (sTREM)-1 in community-acquired pneumonia

1 reference

12 December 2020

Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones

1 reference

12 December 2020

Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils.

1 reference

12 December 2020

Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia

1 reference

12 December 2020

Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia

1 reference

12 December 2020

Neutrophil-toxin interactions promote antigen delivery and mucosal clearance of Streptococcus pneumoniae

1 reference

12 December 2020

Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae

1 reference

12 December 2020

Streptococcus pneumoniae: still a major pathogen

1 reference

12 December 2020

Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis

1 reference

12 December 2020

Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines

1 reference

12 December 2020

Community-acquired pneumonia in the elderly

1 reference

12 December 2020

Impact of initial antibiotic choice on mortality from pneumococcal pneumonia

1 reference

12 December 2020

Early Switch From Intravenous to Oral Antibiotics and Early Hospital Discharge

1 reference

12 December 2020

Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries

1 reference

12 December 2020

Pneumolysin induces the salient histologic features of pneumococcal infection in the rat lung in vivo

1 reference

12 December 2020

Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia

1 reference

12 December 2020

Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia

1 reference

12 December 2020

Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association

1 reference

12 December 2020

10.2165/11585310-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

21275443

Dimensions Publication ID

24 August 2017

0 references

1 reference

PubMed ID

21275443